Johnson & Johnson, it was announced today that Tenoyada (gusekizumab injection (intravenous infusion)) has been launched in China for the treatment of adult patients with moderately to severely active Crohn's disease and ulcerative colitis who have had an inadequate response, loss of response, or intolerance to traditional treatments or biologics.

Tenoyada (gusekizumab injection (intravenous infusion)) was approved in February this year for the induction treatment of moderately to severely active Crohn's disease and in April for the induction treatment of ulcerative colitis. Tenoyada (gusekizumab injection) was approved in 2019 for the treatment of psoriasis, and in February this year, it was expanded to maintenance treatment of moderately to severely active Crohn's disease, and in April, it was expanded to maintenance treatment of ulcerative colitis.

Over the past few decades, the incidence of Crohn's disease and ulcerative colitis in China has continued to rise, and the peak age of onset has shown an earlier trend. These diseases have a profound impact on the life trajectory of patients, affecting their studies, careers and family life. Patients with these two chronic and so far incurable diseases are seeking treatment options that can effectively deal with difficult symptoms and bring lasting relief.

As the first and only fully human inhibitor with dual mechanism of action that can selectively neutralize interleukin-23, Tenoyada and Tenoyada can provide sustained and deep relief in the treatment of Crohn's disease and ulcerative colitis, making it possible for patients to achieve dual control of disease management and life goals.

Huang Chen, President of Johnson & Johnson Innovation Pharmaceuticals China, said: "The simultaneous launch of Tenoyada in Crohn's disease and ulcerative colitis has brought a new standard of treatment to Chinese patients with inflammatory bowel disease (IBD). We will work closely with multiple partners to continuously improve drug accessibility and continue to expand our powerful immune pipeline product portfolio to bring hope to more patients."

Recently, Johnson & Johnson officially launched the "Change IBD" action plan in China, dedicated to comprehensively improving the diagnosis, treatment and living standards of patients with inflammatory bowel disease. The plan focuses on three core areas: strengthening disease education, help improve IBD diagnosis and treatment capabilities, and promote social support for patients, including key projects such as "Double Life" disease education , encouraging patients to improve treatment outcomes and quality of life by participating in "co-decision-making".

https://finance.eastmoney.com/a/202506093425310490.html